Literature DB >> 719130

Daunorubicin, daunorubicinol and DNA plasma kinetics after I.V. administration of daunorubican-DNA complex in the rabbit.

R Hulhoven.   

Abstract

The pharmacokinetics of daunorubicin and daunorubin-DNA complex were studied in the rabbit after i.v. bolus injection and a 4hr infusion period. The plasma levels of daunorubicin and daunorubicinol were measured by high-pressure liquid chromatography and the DNA plasma levels by means of 125I labelled DNA. The results demonstrated a slower distribution of the complex; however, the more rapid decrease in the plasma levels of daunorubicin than that of DNA suggested that this complex essentially constitutes a "daunorubicin circulating pool" from which the drug diffuses more slowly than after the administration of uncomplexed daunorubicin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 719130

Source DB:  PubMed          Journal:  Biomedicine        ISSN: 0300-0893


  5 in total

1.  Daunorubicin-DNA complex in acute nonlymphoblastic leukemia.

Authors:  R Hulhoven; C Harvengt
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.

Authors:  R Hulhoven; G Sokal; C Harvengt
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.

Authors:  S O Nilsson; B Andersson; S Eksborg; M Beran; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Plasma kinetics of mitoxantrone in leukemic patients.

Authors:  R Hulhoven; E Dumont; C Harvengt
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

5.  Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.

Authors:  A Ferrant; R Hulhoven; A Bosly; G Cornu; J L Michaux; G Sokal
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.